Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors - PubMed (original) (raw)

Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors

F Galimi et al. J Cell Biol. 1994 Dec.

Abstract

Hepatocyte growth factor (HGF) is a mesenchymal derived growth factor known to induce proliferation and "scattering" of epithelial and endothelial cells. Its receptor is the tyrosine kinase encoded by the c-MET protooncogene. Here we show that highly purified recombinant HGF stimulates hemopoietic progenitors to form colonies in vitro. In the presence of erythropoietin, picomolar concentrations of HGF induced the formation of erythroid burst-forming unit colonies from CD34-positive cells purified from human bone marrow, peripheral blood, or umbilical cord blood. The growth stimulatory activity was restricted to the erythroid lineage. HGF also stimulated the formation of multipotent CFU-GEMM colonies. This effect is synergized by stem cell factor, the ligand of the tyrosine kinase receptor encoded by the c-KIT protooncogene, which is active on early hemopoietic progenitors. By flow cytometry analysis, the receptor for HGF was found to be expressed on the cell surface in a fraction of CD34+ progenitors. Moreover, in situ hybridization experiments showed that HGF receptor mRNA is highly expressed in embryonic erythroid cells (megaloblasts). HGF mRNA was also found to be produced in the embryonal liver. These data show that HGF plays a direct role in the control of proliferation and differentiation of erythroid progenitors, and they suggest that it may be one of the long-sought mediators of paracrine interactions between stromal and hemopoietic cells within the hemopoietic microenvironment.

PubMed Disclaimer

Cited by

Erythropoietin-independent erythrocyte production: signals through gp130 and c-kit dramatically promote erythropoiesis from human CD34+ cells.
Sui X, Tsuji K, Tajima S, Tanaka R, Muraoka K, Ebihara Y, Ikebuchi K, Yasukawa K, Taga T, Kishimoto T, Nakahata T. Sui X, et al. J Exp Med. 1996 Mar 1;183(3):837-45. doi: 10.1084/jem.183.3.837. J Exp Med. 1996. PMID: 8642288 Free PMC article.
Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Gurska LM, Okabe R, Schurer A, Tong MM, Soto M, Choi D, Ames K, Glushakow-Smith S, Montoya A, Tein E, Miles LA, Cheng H, Hankey-Giblin P, Levine RL, Goel S, Halmos B, Gritsman K. Gurska LM, et al. Clin Cancer Res. 2023 Mar 1;29(5):943-956. doi: 10.1158/1078-0432.CCR-22-1763. Clin Cancer Res. 2023. PMID: 36537918 Free PMC article.
Invasive growth: from development to metastasis.
Comoglio PM, Trusolino L. Comoglio PM, et al. J Clin Invest. 2002 Apr;109(7):857-62. doi: 10.1172/JCI15392. J Clin Invest. 2002. PMID: 11927611 Free PMC article. Review. No abstract available.
Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.
Finisguerra V, Prenen H, Mazzone M. Finisguerra V, et al. Oncogene. 2016 Oct 20;35(42):5457-5467. doi: 10.1038/onc.2016.36. Epub 2016 Mar 21. Oncogene. 2016. PMID: 26996670 Review.
Role of hepatocyte growth factor and its receptor c-met in multiple myeloma.
Seidel C, Børset M, Hjorth-Hansen H, Sundan A, Waage A. Seidel C, et al. Med Oncol. 1998 Sep;15(3):145-53. doi: 10.1007/BF02821933. Med Oncol. 1998. PMID: 9819791 Review.

References

1. Oncogene. 1993 Jul;8(7):2009-14 - PubMed
1. Cell. 1991 Mar 8;64(5):1025-35 - PubMed
1. J Biol Chem. 1992 Oct 5;267(28):20114-9 - PubMed
1. EMBO J. 1991 Oct;10(10):2867-78 - PubMed
1. Oncogene. 1992 Nov;7(11):2195-206 - PubMed

Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors - PubMed (original) (raw)